Quoin Pharmaceuticals, Ltd.
QNRX
$7.20
-$0.0796-1.09%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.45% | -2.26% | -4.21% | -4.75% | -7.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.90% | 21.70% | 1.60% | 1.02% | -5.41% |
| Operating Income | -41.90% | -21.70% | -1.60% | -1.02% | 5.41% |
| Income Before Tax | -47.01% | -24.21% | -3.18% | -0.73% | 15.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -47.01% | -24.21% | -3.18% | -0.73% | 15.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.01% | -24.21% | -3.18% | -0.73% | 15.02% |
| EBIT | -41.90% | -21.70% | -1.60% | -1.02% | 5.41% |
| EBITDA | -42.40% | -21.98% | -1.66% | -1.07% | 5.44% |
| EPS Basic | 78.57% | 80.80% | 77.40% | 69.22% | 50.54% |
| Normalized Basic EPS | 78.57% | 80.80% | 77.40% | 69.22% | 50.54% |
| EPS Diluted | 78.46% | 80.72% | 77.34% | 69.19% | 50.54% |
| Normalized Diluted EPS | 78.57% | 80.80% | 77.40% | 69.22% | 50.54% |
| Average Basic Shares Outstanding | 477.34% | 633.79% | 421.01% | 337.75% | 350.43% |
| Average Diluted Shares Outstanding | 479.73% | 636.59% | 424.14% | 345.83% | 362.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |